Search for: "State v. Lange" Results 41 - 60 of 754
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
26 Aug 2023, 9:16 am by Kluwer Patent blogger
Also, one can search for patents and what the state of affairs is concerning opt outs, oppositions and UPC cases. [read post]
The board’s claim construction and motivation to combine analysis were supported by the record (Shamoon v. [read post]
2 Aug 2023, 2:14 am by Kate O’Sullivan (Bristows)
On 25 July 2023, the Court of Appeal handed down its decision in Teva & Sandoz v Astellas[1] concerning the validity of Astellas’ patent to mirabegron for use in the treatment of overactive bladder (“OAB”). [read post]
30 Jul 2023, 3:05 am by Laurence Lai (Simmons & Simmons LLP)
  Country of origin: new European applications in 2022 v requests for unitary effect   On the other hand, proprietors from Asia and the US appear overall less enthusiastic relative to their proportion of European filings. [read post]
25 Jul 2023, 1:43 am by Matthieu Dhenne (Dhenne Avocats)
Or that the credibility of the technical effect is assessed at the priority or filing date (e.g., TGI Paris, October 6, 2009, RG n°07/16446, Teva v. [read post]
Comment The Court of Appeal noted that it was unfortunate that the trial judge was not referred to Hallen v Brabantia. [read post]
16 Jul 2023, 11:56 pm by Kluwer Patent blogger
Apparently it was also brought forward during the meeting of the EPO’s Administrative Council late June by various member states. [read post]
Although the Court of Appeal was clear, in Neurim v Generics [2020] EWCA Civ 793, that deciding to uphold the lower court’s decision not to grant a pharmaceutical patent PI was based on the specific facts of that case, the Patents Court has subsequently refused two further pharmaceutical PIs (Neurim v Teva [2022] EWHC 954 (Pat) and [2022] EWHC 1641(Pat), and Novartis v Teva [2022] EWHC 959 (Ch)). [read post]
2 Jul 2023, 1:37 am by Laurence Lai (Simmons & Simmons LLP)
Whilst the companies in this top five list are all outside the EU, the 39 member states of the EPO still account for over 45.4% of all opt-outs when looking at the country of the first-named applicant or proprietor. [read post]
29 May 2023, 11:43 am by Kluwer Patent blogger
Furthermore, it should not be forgotten that the participating States in the UPC and UPCA agreement are not the same and that, in the case of the UPCA, they are not all EU Member States. [read post]
14 May 2023, 6:56 pm
 Pix Credit Audience Chamber Piazza della Signoria Apartments of the Priors c. 1543 In the United States at least, there has been an increasing worry about the state of U.S. relations (economic and political) with Latin American states. [read post]
11 May 2023, 2:21 am by Aida Tohala (Bristows)
On 4 May 2023, a mere two weeks after the conclusion of the hearing, the Court of Appeal handed down its decision in Sandoz and Teva v BMS. [read post]
The Regulation is not attempting to establish full transparency, but significantly improve the current state of transparency (or lack thereof) regarding essentiality of patents that are sought to be licensed. [read post]